Literature DB >> 17546598

Gene therapy using ets-1 transcription factor decoy for peritoneal dissemination of gastric cancer.

Hirokazu Taniguchi1, Yoshiyuki Fujiwara, Yuichiro Doki, Yurika Sugita, Itsuro Sohma, Hiroshi Miyata, Shuji Takiguchi, Takushi Yasuda, Naruya Tomita, Ryuichi Morishita, Morito Monden.   

Abstract

The ets-1 transcription factor plays an important role in cell proliferation, differentiation, apoptosis and tissue remodeling. Aberrant ets-1 expression correlates with aggressive tumor behavior and poorer prognosis in patients with various malignancies. This study evaluated the efficacy of double-stranded decoy oligonucleotides targeting ets-1-binding cis elements for the suppression of ets-1 in treatment of a peritoneal dissemination model of gastric cancer. In vitro, MTT assay was performed to evaluate the effect of the ets-1 decoy on cell growth. Electrophoretic mobility shift assay (EMSA) was performed to determine ets-1 activity. In vivo, the effect of the ets-1 decoy was investigated in the peritoneal dissemination nude mice model. Disseminated nodules were analyzed immunohistochemically. Ets-1 decoy, but not scrambled decoy, significantly inhibited cell growth in 2 gastric cancer cell lines, which showed overexpression of ets-1 protein by inhibiting the binding activity of ets-1. In the peritoneal dissemination model, the ets-1 decoy significantly suppressed the disseminated nodules, and tended to prolong the survival rate. PCNA index, microvessel density and VEGF expression were also reduced in peritoneal tumors treated with ets-1 decoy. Intraperitoneal injection of ets-1 decoy inhibited peritoneal dissemination of gastric cancer in a nude mice model. The results indicate that the decoy strategy for ets-1 offers a promising therapy for patients with incurable peritoneal dissemination of gastric cancer, most of which show overexpression of ets-1 protein.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17546598     DOI: 10.1002/ijc.22870

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  11 in total

1.  Knockdown of linc00152 inhibits the progression of gastric cancer by regulating microRNA-193b-3p/ETS1 axis.

Authors:  Haifang Wang; Wenxiang Chen; Peng Yang; Jun Zhou; Kaiyuan Wang; Qingchun Tao
Journal:  Cancer Biol Ther       Date:  2018-11-07       Impact factor: 4.742

Review 2.  Drugging the undruggable: transcription therapy for cancer.

Authors:  Chunhong Yan; Paul J Higgins
Journal:  Biochim Biophys Acta       Date:  2012-11-09

3.  Photochemical control of DNA decoy function enables precise regulation of nuclear factor κB activity.

Authors:  Jeane M Govan; Mark O Lively; Alexander Deiters
Journal:  J Am Chem Soc       Date:  2011-07-29       Impact factor: 15.419

4.  Ets-1 upregulation mediates angiotensin II-related cardiac fibrosis.

Authors:  Guanghua Hao; Zhenhua Han; Zhe Meng; Jin Wei; Dengfeng Gao; Hong Zhang; Nanping Wang
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

5.  Gambogic acid-loaded magnetic Fe(3)O(4) nanoparticles inhibit Panc-1 pancreatic cancer cell proliferation and migration by inactivating transcription factor ETS1.

Authors:  Cailian Wang; Haijun Zhang; Yan Chen; Fangfang Shi; Baoan Chen
Journal:  Int J Nanomedicine       Date:  2012-02-14

Review 6.  Recent advances in the structural molecular biology of Ets transcription factors: interactions, interfaces and inhibition.

Authors:  Christopher D O Cooper; Joseph A Newman; Opher Gileadi
Journal:  Biochem Soc Trans       Date:  2014-02       Impact factor: 5.407

Review 7.  Crosstalk of the Androgen Receptor with Transcriptional Collaborators: Potential Therapeutic Targets for Castration-Resistant Prostate Cancer.

Authors:  Daisuke Obinata; Kenichi Takayama; Satoru Takahashi; Satoshi Inoue
Journal:  Cancers (Basel)       Date:  2017-02-28       Impact factor: 6.639

Review 8.  ETS-targeted therapy: can it substitute for MEK inhibitors?

Authors:  Osamu Tetsu; Frank McCormick
Journal:  Clin Transl Med       Date:  2017-05-02

9.  The level of Ets-1 protein is regulated by poly(ADP-ribose) polymerase-1 (PARP-1) in cancer cells to prevent DNA damage.

Authors:  Arnaud J Legrand; Souhaila Choul-Li; Corentin Spriet; Thierry Idziorek; Dorothée Vicogne; Hervé Drobecq; Françoise Dantzer; Vincent Villeret; Marc Aumercier
Journal:  PLoS One       Date:  2013-02-06       Impact factor: 3.240

10.  miR-144-3p, a tumor suppressive microRNA targeting ETS-1 in laryngeal squamous cell carcinoma.

Authors:  Si-Yi Zhang; Zhong-Ming Lu; Ye-Feng Lin; Liang-Si Chen; Xiao-Ning Luo; Xin-Han Song; Shao-Hua Chen; Yi-Long Wu
Journal:  Oncotarget       Date:  2016-03-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.